Abstract

The Cancer Research Center of the University of North Carolina was established in 1975 to promote interdisciplinary cancer-related research. The Cancer is now a well established entity with research programs in Tumor Immunology, Tumor Virology, Cancer Cell Biology, Chemical Carcinogenesis, Drug Development, Cancer Epidermiology, Clinical Research and Cancer Control with 80 core faculty and a newly constructed 36,000 net square foot research building. In this, our third renewal application, we request: 1. Support for the Cancer Research Center senior leadership, faculty active in cancer-related research who plan, organize and implement the cancer effort at the University of North Carolina. 2. Support for selected Cancer Center staff investigators following NCI guidelines. 3. Provision of support for the administrative functions of the Center. 4. Support for continuation of the established Cancer Research Center core facilities plus one new core facility. 5. Support for recruitment of faculty members in specific areas critical to the further development of our programs.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-12
Application #
3101549
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1981-08-01
Project End
1989-07-31
Budget Start
1986-08-01
Budget End
1987-07-31
Support Year
12
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
University of North Carolina Chapel Hill
Department
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599

  Publications

Cameron, Jennifer E; Rositch, Anne F; Vielot, Nadja A et al. (2018) Epstein-Barr Virus, High-Risk Human Papillomavirus and Abnormal Cervical Cytology in a Prospective Cohort of African Female Sex Workers. Sex Transm Dis 45:666-672
Lim, Joseph K; Liapakis, Ann Marie; Shiffman, Mitchell L et al. (2018) Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 16:1811-1819.e4
Wang, Gary P; Terrault, Norah; Reeves, Jacqueline D et al. (2018) Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection. Sci Rep 8:3199
Phillips, Bonnie; Van Rompay, Koen K A; Rodriguez-Nieves, Jennifer et al. (2018) Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. J Virol 92:
Lianga, Noel; Doré, Carole; Kennedy, Erin K et al. (2018) Cdk1 phosphorylation of Esp1/Separase functions with PP2A and Slk19 to regulate pericentric Cohesin and anaphase onset. PLoS Genet 14:e1007029
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Dhungel, Bal Mukunda; Montgomery, Nathan D; Painschab, Matthew S et al. (2018) 'Discovering' primary effusion lymphoma in Malawi. AIDS 32:2264-2266
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Stanley, Christopher C; van der Gronde, Toon; Westmoreland, Kate D et al. (2018) Risk factors and reasons for treatment abandonment among children with lymphoma in Malawi. Support Care Cancer 26:967-973
Dronamraju, Raghuvar; Jha, Deepak Kumar; Eser, Umut et al. (2018) Set2 methyltransferase facilitates cell cycle progression by maintaining transcriptional fidelity. Nucleic Acids Res 46:1331-1344

Showing the most recent 10 out of 1525 publications